Aromatase inhibition: A potential target for the management of recurrent or metastatic endometrial cancer by letrozole: More questions than answers?

Expert Opinion on Investigational Drugs

Volumn 20, Issue 5, 2011, Pages 681-690

  Steed, Helen L ^a,b   Chu, Quincy S C ^a,b  

^a CROSS CANCER INSTITUTE   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

aromatase; aromatase inhibitor; endometrial cancer; letrozole

Indexed keywords

ANASTROZOLE; AROMATASE; CARBOPLATIN; CISPLATIN; ESTROGEN; ESTROGEN RECEPTOR; EXEMESTANE; GESTAGEN; LETROZOLE; PACLITAXEL; PROGESTERONE; TAMOXIFEN; TUMOR MARKER;

ANEMIA; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; DEEP VEIN THROMBOSIS; DEPRESSION; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENDOMETRIUM; ENDOMETRIUM CANCER; ENZYME INHIBITION; FATIGUE; FEMALE; HORMONAL THERAPY; HOT FLUSH; HUMAN; METASTASIS; NEPHROTOXICITY; NEUROTOXICITY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); TREATMENT RESPONSE; VOMITING;

AROMATASE INHIBITORS; CLINICAL TRIALS AS TOPIC; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NITRILES; TRIAZOLES;

EID: 79953647162     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2011.566862     Document Type: Review

References (97)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;20:225-49
2. Sorosky JI. Endometrial cancer. Obstet Gynecol 2008;111:436-47 (Pubitemid 351653438)
3. Watson P, Lynch HT. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 1993;71:677-85 (Pubitemid 23051366)
4. Tinelli A, Vergara D, Martignago R, et al. Hormonal carcinogenesis and socio-biological development factors in endometrial cancer: a clinical review. Acta Obstet Gynecol Scand 2008;87:1101-13
5. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10-17 (Pubitemid 13194678)
6. Sherman ME, Kurman RJ. Evolving concepts in endometrial carcinogenesis: importance of DNA repair and deregulated growth. Hum Pathol 1998;29:1035-8 (Pubitemid 28467519)
7. Koul A, Willen R, Bendahl PO, et al. Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis. Cancer 2002;94:2369-79 (Pubitemid 34457118)
8. Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch 2004;444:213-23 (Pubitemid 38446432)
9. Luesley D, Lawton FG, Berchuck A. Uterine cancer. Taylor & Francis, New York; 2006
10. Humber CE, Tierney JF, Symonds RP, et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Ann Oncol 2007;18:409-20 (Pubitemid 46359618)
11. Cornelison TL, Baker TR, Piver MS, et al. Cisplatin, adriamycin, etoposide, megestrol acetate versus melphalan, 5-fluorouracil, medroxyprogesterone acetate in the treatment of endometrial carcinoma. Gynecol Oncol 1995;59:243-8
12. Gebbia V, Testa A, Borsellino N, et al. Cisplatin and vinorelbine in advanced and/or metastatic adenocarcinoma of the endometrium: a new highly active chemotherapeutic regimen. Ann Oncol 2001;12:767-72 (Pubitemid 32655084)
13. Green JB III, Green S, Alberts DS, et al. Carboplatin therapy in advanced endometrial cancer. Obstet Gynecol 1990;75:696-700 (Pubitemid 20110194)
14. Long HJ, Pfeifle DM, Wieand HS, et al. Phase II evaluation of carboplatin in advanced endometrial carcinoma. J Natl Cancer Inst 1988;80:276-8
15. Hoskins PJ, Swenerton KD, Pike JA, et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a Phase II study. J Clin Oncol 2001;19:4048-53 (Pubitemid 32976691)
16. van Wijk FH, van der Burg ME, Burger CW, et al. Management of recurrent endometrioid endometrial carcinoma: an overview. Int J Gynecol Cancer 2009;19:314-20
17. Ma BB, Oza A, Eisenhauer E, et al. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers--a study of the National Cancer Institute of Canada Clinical Trials Group. Int J Gynecol Cancer 2004;14:650-8 (Pubitemid 39062922)
18. Gehrig PA, Bae-Jump VL. Promising novel therapies for the treatment of endometrial cancer. Gynecol Oncol 2010;116:187-94
19. Konecny GE, Venkatesan N, Yang G, et al. Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. Br J Cancer 2008;98:1076-84 (Pubitemid 351399811)
20. Engelsen IB, Akslen LA, Salvesen HB. Biologic markers in endometrial cancer treatment. APMIS 2009;117:693-707
21. Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: the second decade. Cell 1995;83:835-9
22. Hall JM, McDonnell DP. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 1999;140:5566-78 (Pubitemid 30645344)
23. Watanabe T, Inoue S, Hiroi H, et al. Isolation of estrogen-responsive genes with a CpG island library. Mol Cell Biol 1998;18:442-9 (Pubitemid 28021055)
24. Kushner PJ, Agard DA, Greene GL, et al. Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 2000;74:311-17 (Pubitemid 32126243)
25. Shang Y, Hu X, DiRenzo J, et al. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 2000;103:843-52
26. Smith CL, O'Malley BW. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 2004;25:45-71 (Pubitemid 38292038)
27. Shemshedini L, Knauthe R, Sassone-Corsi P, et al. Cell-specific inhibitory and stimulatory effects of Fos and Jun on transcription activation by nuclear receptors. EMBO J 1991;10:3839-49 (Pubitemid 21905412)
28. Matthews J, Wihlen B, Tujague M, et al. Estrogen receptor (ER) beta modulates ERalpha-mediated transcriptional activation by altering the recruitment of c-Fos and c-Jun to estrogen-responsive promoters. Mol Endocrinol 2006;20:534-43 (Pubitemid 43292585)
29. Moriarty K, Kim KH, Bender JR. Minireview: estrogen receptor-mediated rapid signaling. Endocrinology 2006;147:5557-63 (Pubitemid 44833471)
30. Couse JF, Curtis Hewitt S, Korach KS. Receptor null mice reveal contrasting roles for estrogen receptor alpha and beta in reproductive tissues. J Steroid Biochem Mol Biol 2000;74:287-96 (Pubitemid 32126241)
31. Fujishita A, Nakane PK, Koji T, et al. Expression of estrogen and progesterone receptors in endometrium and peritoneal endometriosis: an immunohistochemical and in situ hybridization study. Fertil Steril 1997;67:856-64 (Pubitemid 27183914)
32. Kuiper GG, Carlsson B, Grandien K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997;138:863-70 (Pubitemid 27089735)
33. Barkhem T, Nilsson S, Gustafsson JA. Molecular mechanisms, physiological consequences and pharmacological implications of estrogen receptor action. Am J Pharmacogenomics 2004;4:19-28 (Pubitemid 38325702)
34. Lecce G, Meduri G, Ancelin M, et al. Presence of estrogen receptor beta in the human endometrium through the cycle: expression in glandular, stromal, and vascular cells. J Clin Endocrinol Metab 2001;86:1379-86 (Pubitemid 32323031)
35. Weihua Z, Saji S, Makinen S, et al. Estrogen receptor (ER) beta, a modulator of ERalpha in the uterus. Proc Natl Acad Sci USA 2000;97:5936-41 (Pubitemid 30367502)
36. Fu M, Wang C, Zhang X, et al. Nuclear receptor modifications and endocrine cell proliferation. J Steroid Biochem Mol Biol 2003;85:133-8 (Pubitemid 37011091)
37. Wang C, Fu M, Angeletti RH, et al. Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity. J Biol Chem 2001;276:18375-83
38. Tateishi Y, Kawabe Y, Chiba T, et al. Ligand-dependent switching of ubiquitin-proteasome pathways for estrogen receptor. EMBO J 2004;23:4813-23 (Pubitemid 40069711)
39. McDonnell DP, Norris JD. Connections and regulation of the human estrogen receptor. Science 2002;296:1642-4 (Pubitemid 34579150)
40. McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 1999;20:321-44 (Pubitemid 30649811)
41. Geisinger KR, Marshall RB, Kute TE, et al. Correlation of female sex steroid hormone receptors with histologic and ultrastructural differentiation in adenocarcinoma of the endometrium. Cancer 1986;58:1506-17 (Pubitemid 16016837)
42. Carcangiu ML, Chambers JT, Voynick IM, et al. Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part I: clinical and histologic correlations. Am J Clin Pathol 1990;94:247-54 (Pubitemid 20275337)
43. Jazaeri AA, Nunes KJ, Dalton MS, et al. Well-differentiated endometrial adenocarcinomas and poorly differentiated mixed mullerian tumors have altered ER and PR isoform expression. Oncogene 2001;20:6965-9 (Pubitemid 33052187)
44. Pathirage N, Di Nezza LA, Salmonsen LA, et al. Expression of aromatase, estrogen receptors, and their coactivators in patients with endometrial cancer. Fertil Steril 2006;86:469-72 (Pubitemid 44118947)
45. Chambers JT, MacLusky N, Eisenfield A, et al. Estrogen and progestin receptor levels as prognosticators for survival in endometrial cancer. Gynecol Oncol 1988;31:65-81
46. Creasman WT. Prognostic significance of hormone receptors in endometrial cancer. Cancer 1993;71:1467-70 (Pubitemid 23056062)
47. Kadar N, Malfetano JH, Homesley HD. Steroid receptor concentrations in endometrial carcinoma: effect on survival in surgically staged patients. Gynecol Oncol 1993;50:281-6 (Pubitemid 23299719)
48. Sivridis E, Giatromanolaki A, Koukourakis M, et al. Endometrial carcinoma: association of steroid hormone receptor expression with low angiogenesis and bcl-2 expression. Virchows Arch 2001;438:470-7 (Pubitemid 32449055)
49. Ehrlich CE, Young PC, Stehman FB, et al. Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. Am J Obstet Gynecol 1988;158:796-807
50. Judd HL, Shamonki IM, Frumar AM, et al. Origin of serum estradiol in postmenopausal women. Obstet Gynecol 1982;59:680-6 (Pubitemid 12107424)
51. Bulun SE, Zeitoun K, Sasano H, et al. Aromatase in aging women. Semin Reprod Endocrinol 1999;17:349-58 (Pubitemid 30256593)
52. Naitoh K, Honjo H, Yamamoto T, et al. Estrone sulfate and sulfatase activity in human breast cancer and endometrial cancer. J Steroid Biochem 1989;33:1049-54 (Pubitemid 20036137)
53. Berstein LM, Tchernobrovkina AE, Gamajunova VB, et al. Tumor estrogen content and clinico-morphological and endocrine features of endometrial cancer. J Cancer Res Clin Oncol 2003;129:245-9 (Pubitemid 36713801)
54. Ito K, Utsunomiya H, Suzuki T, et al. 17beta-hydroxysteroid dehydrogenases in human endometrium and its disorders. Mol Cell Endocrinol 2006;248:136-40
55. Bonney RC, Scanlon MJ, Jones DL, et al. The relationship between oestradiol metabolism and adrenal steroids in the endometrium of postmenopausal women with and without endometrial cancer. Eur J Cancer Clin Oncol 1986;22:953-61 (Pubitemid 16035147)
56. Vermeulen-Meiners C, Poortman J, Haspels AA, et al. The endogenous concentration of estradiol and estrone in pathological human postmenopausal endometrium. J Steroid Biochem 1986;24:1073-8 (Pubitemid 16034853)
57. Yamamoto T, Kitawaki J, Urabe M, et al. Estrogen productivity of endometrium and endometrial cancer tissue; influence of aromatase on proliferation of endometrial cancer cells. J Steroid Biochem Mol Biol 1993;44:463-8 (Pubitemid 23126618)
58. Watanabe K, Sasano H, Harada N, et al. Aromatase in human endometrial carcinoma and hyperplasia. Immunohistochemical, in situ hybridization, and biochemical studies. Am J Pathol 1995;146:491-500
59. Takahashi-Shiga N, Utsunomiya H, Miki Y, et al. Local biosynthesis of estrogen in human endometrial carcinoma through tumor-stromal cell interactions. Clin Cancer Res 2009;15:6028-34
60. Segawa T, Shozu M, Murakami K, et al. Aromatase expression in stromal cells of endometrioid endometrial cancer correlates with poor survival. Clin Cancer Res 2005;11:2188-94 (Pubitemid 40490177)
61. Morsi HM, Leers MP, Nap M, et al. Apoptosis and anti-apoptosis in oestrogen-receptor negative endometrial cancer cells in response to anastrozole, 4-hydroxytamoxifen and medroxyprogesterone acetate. Eur J Cancer 2000;36(Suppl 4):112-13
62. Sasano H, Sato S, Ito K, et al. Effects of aromatase inhibitors on the pathobiology of the human breast, endometrial and ovarian carcinoma. Endocr Relat Cancer 1999;6:197-204 (Pubitemid 29260052)
63. Miller WR, Anderson TJ, Evans DB, et al. An integrated view of aromatase and its inhibition. J Steroid Biochem Mol Biol 2003;86:413-21 (Pubitemid 37420005)
64. Matsumoto M, Yamaguchi Y, Seino Y, et al. Estrogen signaling ability in human endometrial cancer through the cancer-stromal interaction. Endocr Relat Cancer 2008;15:451-63 (Pubitemid 351880834)
65. Cole PA, Robinson CH. Mechanism and inhibition of cytochrome P-450 aromatase. J Med Chem 1990;33:2933-42
66. Soudon J. Comparison of in vitro exemestane activity versus other antiaromatase agents. Clin Breast Cancer 2000;1(Suppl 1):S68-73
67. Sioufi A, Sandrenan N, Godbillon J, et al. Comparative bioavailability of letrozole under fed and fasting conditions in 12 healthy subjects after a 2.5 mg single oral administration. Biopharm Drug Dispos 1997;18:489-97 (Pubitemid 27338980)
68. Keating GM. Letrozole: a review of its use in the treatment of postmenopausal women with hormone-responsive early breast cancer. Drugs 2009;69:1681-705
69. Pfister CU, Martoni A, Zamagni C, et al. Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara) in breast cancer patients. Biopharm Drug Dispos 2001;22:191-7 (Pubitemid 33133815)
70. Berstein L, Maximov S, Gershfeld E, et al. Neoadjuvant therapy of endometrial cancer with the aromatase inhibitor letrozole: endocrine and clinical effects. Eur J Obstet Gynecol Reprod Biol 2002;105:161-5
71. Berstein L, Kovalevskij A, Zimarina T, et al. Aromatase and comparative response to its inhibitors in two types of endometrial cancer. J Steroid Biochem Mol Biol 2005;95:71-4 (Pubitemid 41137296)
72. Barker LC, Brand IR, Crawford SM. Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma. Curr Med Res Opin 2009;25:1105-9
73. Novartis Pharmaceuticals. Letrozole in the Treatment of Advanced or Recurrent Hormone Receptor Positive Endometrial Cancer. ClinicalTrials.gov NCT00171808. Available from: http://clinicaltrials.gov/ct2/show/NCT00171808? term=NCT00171808&rank=1
74. Novartis. A Study of Letrozole in the Treatment of Endometrial Cancer. ClinicalTrials.gov NCT00333086. Available from: http://clinicaltrials.gov/ct2/ show/NCT00333086?term=NCT00333086&rank=1
75. Singh M, Zaino RJ, Filiaci VJ, et al. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 2007;106:325-33 (Pubitemid 47087930)
76. Bryant W, Snowhite AE, Rice LW, et al. The estrogen receptor (ER)alpha variant Δ5 exhibits dominant positive activity on ER-regulated promoters in endometrial carcinoma cells. Endocrinology 2005;146:751-9 (Pubitemid 40129831)
77. Lin SL, Yan LY, Liang XW, et al. A novel variant of ER-alpha, ER-alpha36 mediates testosterone-stimulated ERK and Akt activation in endometrial cancer Hec1A cells. Reprod Biol Endocrinol 2009;7:102
78. Ogawa S, Inoue S, Watanabe T, et al. Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor ofestrogen action in human. Nucleic Acids Res 1998;26:3505-12 (Pubitemid 28347221)
79. Ingle JN. Pharmacogenomics of tamoxifen and aromatase inhibitors. Cancer 2008;112:695-9 (Pubitemid 351186391)
80. Chaudhry P, Asselin E. Resistance to chemotherapy and hormone therapy in endometrial cancer. Endocr Relat Cancer 2009;16:363-80
81. Slomovitz BM, Lu KH, Johnston T, et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer 2010;116:5415-19
82. Oza A, Elit L, Provencher D. NCIC Clinical Trials Group. A phase II study of temsirlolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b. J Clin Oncol 2008;26(20 Suppl):abstract 5516
83. Oza A, Elit L, Jea B. Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer-NCIC IND 160. J Clin Oncol 2006;24(18S):abstract 3003
84. Colombo N, McMeeklin S, Schwartz P. A phase II study of the mTOR inhibitor AP23572 as a single agent in advanced endometrial cancer. J Clin Oncol 2007;25:abstract 5516
85. Gadducci A, Cosio S, Genazzani AR. Tissue and serum biomarkers as prognostic variables in endometrioid-type endometrial cancer. Crit Rev Oncol Hematol 2010: published online 4 December 2010, doi:10.1016/j. critrevonc.2010.11.005
86. Gadducci A, Sartori E, Landoni F, et al. The prognostic relevance of histological type in uterine sarcomas: a Cooperation Task Force (CTF) multivariate analysis of 249 cases. Eur J Gynaecol Oncol 2002;23:295-9 (Pubitemid 34948043)
87. Lu KH, Wu W, Dave B, et al. Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma. Clin Cancer Res 2008;14:2543-50
88. Kurokawa H, Lenferink AE, Simpson JF, et al. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 2000;60:5887-94
89. Kurokawa H, Arteaga CL. ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clin Cancer Res 2003;9:511S-5S
90. Stoica GE, Franke TF, Moroni M, et al. Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway. Oncogene 2003;22:7998-8011 (Pubitemid 37175864)
91. Stoica GE, Franke TF, Wellstein A, et al. Estradiol rapidly activates Akt via the ErbB2 signaling pathway. Mol Endocrinol 2003;17:818-30 (Pubitemid 36539574)
92. Perez-Tenorio G, Stal O. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 2002;86:540-5 (Pubitemid 34185089)
93. Wahl H, Daudi S, Kshirsagar M, et al. Expression of metabolically targeted biomarkers in endometrial carcinoma. Gynecol Oncol 2010;116:21-7
94. Xie Y, Wang YL, Yu L, et al. Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells. J Steroid Biochem Mol Biol 2010: published online 17 December 2010, doi:10.1016/j.jsbmb.2010.12.006
95. Darb-Esfahani S, Faggad A, Noske A, et al. Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro. J Cancer Res Clin Oncol 2009;135:933-41
96. Bae-Jump VL, Zhou C, Boggess JF, et al. Rapamycin inhibits cell proliferation in type I and type II endometrial carcinomas: a search for biomarkers of sensitivity to treatment. Gynecol Oncol 2010;119:579-85
97. Bhatnagar AS. The discovery and mechanism of action of letrozole. Breast Cancer Res Treat 2007;105(Suppl 1):7-17 (Pubitemid 47524797)